TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25344520

Group type: EXPERIMENTAL
Intervention: Plasma P. falciparum DNA concentrations
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Plasma P. falciparum DNA concentrations plus plasma P. falciparum HRP2 concentrations
Number of subjects: 435

Group type: COMPARATOR
Intervention: Plasma P. falciparum HRP2 concentrations alone
Number of subjects: 435

Group type: COMPARATOR
Intervention: Parasite densities
Number of subjects: 435
Study: 24383478

Group type: EXPERIMENTAL
Intervention: Erythromycin IV 150 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Morphine IV 0.05 mg/kg BW
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study: 21942234

Group type: COMPARATOR
Intervention: Indirect conventional crowns retained by glass fiber posts (Group GC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Endocrowns (Group GE)
Number of subjects: 20
Study: 20071898

Group type: EXPERIMENTAL
Intervention: Core competency support program
Number of subjects: 56
Study: 17539713

Group type: EXPERIMENTAL
Intervention: Dentifrice
Number of subjects: 36

Group type: COMPARATOR
Intervention: No dentifrice
Number of subjects: 36
Study: 15031275

Group type: EXPERIMENTAL
Intervention: Introductory postcard sent
Number of subjects: 348

Group type: COMPARATOR
Intervention: No introductory postcard sent
Number of subjects: 348
Study: 11536417

Group type: EXPERIMENTAL
Intervention: Sleep therapy programme (six-session group programme including stimulus control therapy, relaxation training, and other strategies)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sleep therapy programme
Number of subjects: 12
Study: 9604143

Group type: EXPERIMENTAL
Intervention: 10 mg KW-4679 (single-dose trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg KW-4679 (multiple-dose trial)
Number of subjects: 0
Study: 8027959

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Social stress
Number of subjects: 24

Group type: COMPARATOR
Intervention: Degree of neurological impairment, specific neurological symptoms, disability or handicap
Number of subjects: 24
Study: 3421805

Group type: EXPERIMENTAL
Intervention: Nortriptyline hydrochloride
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 31413313

Group type: EXPERIMENTAL
Intervention: Tacrolimus and mTOR inhibitor (second-line treatment)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tacrolimus and mTOR inhibitor (third-line treatment)
Number of subjects: 42
Study: 30920339

Group type: EXPERIMENTAL
Intervention: CDP-choline (500 mg) and galantamine (16 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28753920

Group type: EXPERIMENTAL
Intervention: Otto the Auto website
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control website
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Otto the Auto website with parental engagement
Number of subjects: 69
Study: 25135348

Group type: EXPERIMENTAL
Intervention: Intravenous glucose-insulin-potassium (GIK) therapy
Number of subjects: 0
Study: 24568002

Group type: EXPERIMENTAL
Intervention: Beech Brook Therapy Assessment Instrument
Number of subjects: 6
Study: 21467230

Group type: EXPERIMENTAL
Intervention: Total NNAL in urine
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Total nicotine in urine
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Total cotinine in urine
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: iso-NNAL in urine
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Exposure levels
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Demographic comparison
Number of subjects: 79
Study: 17530154

Group type: EXPERIMENTAL
Intervention: Supervised pelvic floor muscle training (PFMT)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 268
Study: 17157592

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% topical therapy with reduced drop-skin contact (eye 1)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Bimatoprost 0.03% topical therapy (fellow eye)
Number of subjects: 2
Study: 14581436

Group type: COMPARATOR
Intervention: Intravesical instillations of mitomycin C (MMC) alone
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: MMC in combination with local microwave-induced hyperthermia
Number of subjects: 83
Study: 10977126

Group type: EXPERIMENTAL
Intervention: Gelfoam disc impregnated with 0.60 mg of tropicamide racemate and 1.7 mg of 1‐phenylephrine hydrochloride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Topically administered drops (phenylephrine hydrochloride 2.5% solution and tropicamide 1% solution)
Number of subjects: 20
Study: 8956088

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 1556221

Group type: EXPERIMENTAL
Intervention: Support and sleep hygiene
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Support and sleep hygiene plus progressive relaxation
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Support and sleep hygiene plus stimulus control
Number of subjects: 53

Group type: COMPARATOR
Intervention: Measurement control group
Number of subjects: 53
Study: 3892854

Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 165

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 165
Study: 30591320

Group type: EXPERIMENTAL
Intervention: TY 4mg
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: TY 8mg
Number of subjects: 220

Group type: COMPARATOR
Intervention: BO 2.5mg
Number of subjects: 220

Group type: COMPARATOR
Intervention: BO 5mg
Number of subjects: 220
Study: 28327140

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2313

Group type: COMPARATOR
Intervention: Canagliflozin
Number of subjects: 2313
Study: 27701496

Group type: EXPERIMENTAL
Intervention: In-office bleaching with 35% hydrogen peroxide and different light activation protocols
Number of subjects: 40

Group type: COMPARATOR
Intervention: In-office bleaching with 35% hydrogen peroxide
Number of subjects: 40
Study: 24067879

Group type: EXPERIMENTAL
Intervention: Telbivudine (600 mg/d)
Number of subjects: 0
Study: 23115407

Group type: EXPERIMENTAL
Intervention: 5 consecutive 10.7-h night shifts
Number of subjects: 29

Group type: COMPARATOR
Intervention: 3 consecutive days off duty
Number of subjects: 29
Study: 19933245

Group type: EXPERIMENTAL
Intervention: DVD
Number of subjects: 189

Group type: COMPARATOR
Intervention: Classroom-based instruction
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Class plus DVD
Number of subjects: 189
Study: 16741368

Group type: EXPERIMENTAL
Intervention: Active treatment (once daily SLIT) with 10 days updosing (T1), 20 days maintenance treatment (T2), and 2 consecutive months on maintenance treatment (T3 and T4)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo treatment with placebo updosing (T1), placebo maintenance (T2), initiated active treatment at T3, and continued active treatment until the end of the study (T4)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Active treatment (once daily SLIT)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 135
Study: 14703417

Group type: EXPERIMENTAL
Intervention: Aprotinin (loading dose of 2 x 10(6) KIU followed by continuous infusion of 0.5 x 10(6) KIU/h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 24
Study: 10892227

Group type: EXPERIMENTAL
Intervention: Attention problems
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Inattentive first graders with normal reading scores after kindergarten
Number of subjects: 387
Study: 8936577

Group type: EXPERIMENTAL
Intervention: 3-day interactive workshop on disease prevention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no workshop)
Number of subjects: 34
Study: 1555479

Group type: EXPERIMENTAL
Intervention: Streptokinase and subcutaneous heparin
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Streptokinase and intravenous heparin
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Front-loaded, weight-adjusted rt-PA and intravenous heparin
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Combination of streptokinase and rt-PA and intravenous heparin
Number of subjects: 40000
Study: 3921279

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (60 mg/24 hr)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31007691

Group type: EXPERIMENTAL
Intervention: Low-energy diet
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (fish oil) 1500 mg/d
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study: 28811095

Group type: EXPERIMENTAL
Intervention: Clinitas Soothe
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hyabak
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TheraTears
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tears Again
Number of subjects: 50
Study: 26636393

Group type: EXPERIMENTAL
Intervention: Conventional extracorporeal circulation (CECC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Minimized extracorporeal circulation (MECC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Off‐pump coronary artery bypass grafting (OPCAB)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Heparin management
Number of subjects: 120

Group type: COMPARATOR
Intervention: Overall renal function parameters
Number of subjects: 120
Study: 24851845

Group type: EXPERIMENTAL
Intervention: Earplug technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 22569432

Group type: EXPERIMENTAL
Intervention: Oral L-carnitine (LC) supplementation, 250 mg tablets three times a day for eight weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 20485941

Group type: EXPERIMENTAL
Intervention: Positive reinforcement during spirometry (only in intervention group)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no positive reinforcement)
Number of subjects: 105
Study: 18823152

Group type: COMPARATOR
Intervention: Testosterone modified to match levels of younger men for 6 weeks; conversion of testosterone to estradiol blocked; production of testosterone blocked; placebo (no treatment)
Number of subjects: 0
Study: 16022960

Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing
Number of subjects: 431

Group type: COMPARATOR
Intervention: Shock therapy
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Patients with LBBB
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Patients with RBBB and nonspecific IVCD
Number of subjects: 431
Study: 12512893

Group type: EXPERIMENTAL
Intervention: Preradiotherapy ventilation tube insertion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 0
Study: 10513773

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Abciximab (reteplase)
Number of subjects: 392
Study: 8953409

Group type: EXPERIMENTAL
Intervention: Liposomal ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain drug ointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liposomal formulations with ultrasound
Number of subjects: 0
Study: 2007326

Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 206

Group type: COMPARATOR
Intervention: Benazepril 2, 5, and 10 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Open-label Hydrochlorothiazide (25 mg/day) added to benazepril, hydrochlorothiazide, or placebo
Number of subjects: 206
Study: 7097736

Group type: EXPERIMENTAL
Intervention: 45‐minute videotape lecture discussing practical issues of the diagnosis and management of children with meningomyelocele
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 78
Study: 31420350

Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Number of subjects: 2818

Group type: COMPARATOR
Intervention: Reference erythropoiesis-stimulating agents
Number of subjects: 2818
Study: 28829488

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 74
Study: 26027881

Group type: EXPERIMENTAL
Intervention: Elective node dissection (ipsilateral neck dissection at the time of primary surgery)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Therapeutic node dissection (watchful waiting followed by neck dissection for nodal relapse)
Number of subjects: 500
Study: 23642145

Group type: EXPERIMENTAL
Intervention: Coordinated care program (Care Navigation)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 500
Study: 21302117

Group type: EXPERIMENTAL
Intervention: Surgical bowel occlusion (no-touch group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no surgical bowel occlusion)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups with saline irrigation of 400 ml or more
Number of subjects: 32
Study: 19530582

Group type: EXPERIMENTAL
Intervention: Vicryl Plus (antibacterial suture)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vicryl (traditional braided suture)
Number of subjects: 100
Study: 17352567

Group type: EXPERIMENTAL
Intervention: High-intoxication group
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Intermediate-intoxication group
Number of subjects: 101

Group type: COMPARATOR
Intervention: No-intoxication control group
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Low-intoxication group
Number of subjects: 101
Study: 12913686

Group type: EXPERIMENTAL
Intervention: Subcostal mini incision donor nephrectomy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Transcostal mini incision donor nephrectomy
Number of subjects: 82
Study: 10481417

Group type: EXPERIMENTAL
Intervention: Propofol injected at a rate of 800 ml/hr after fentanyl 100 micrograms
Number of subjects: 55

Group type: COMPARATOR
Intervention: Propofol injected at a rate of 1 ml/s after fentanyl 100 micrograms
Number of subjects: 55
Study: 8984708

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 400 micrograms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 800 micrograms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1250 micrograms
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Budesonide 1250 micrograms
Number of subjects: 10
Study: 1681840

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 micrograms kg‐1
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Midazolam 0.08 mg kg‐1
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 6751243

Group type: EXPERIMENTAL
Intervention: Zinc sulphate
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31411972

Group type: EXPERIMENTAL
Intervention: 90-day percentage erection fullness score (0-24% or 25-100%)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: 90-day percentage erection fullness score
Number of subjects: 388
Study: 31648845

Group type: EXPERIMENTAL
Intervention: Initial combination therapy (ambrisentan and tadalafil)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Pooled monotherapy (ambrisentan or tadalafil)
Number of subjects: 500
Study: 28481761

Group type: EXPERIMENTAL
Intervention: Narrative Expressive Writing
Number of subjects: 109

Group type: COMPARATOR
Intervention: Traditional Expressive Writing
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control Writing Condition
Number of subjects: 109
Study: 25950389

Group type: EXPERIMENTAL
Intervention: Preoperative subpterygial Mitomycin C injection (0.1mL 0.015% MMC)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Intraoperative subpterygial Mitomycin C injection (0.1mL 0.015% MMC)
Number of subjects: 83
Study: 24321802

Group type: EXPERIMENTAL
Intervention: SMART regimen (budesonide-formoterol 200 μg and 6 μg per actuation, twice daily, plus as needed)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: SMART regimen
Number of subjects: 303
Study: 22125425

Group type: EXPERIMENTAL
Intervention: Double cervical cerclage (addition to McDonald cerclage)
Number of subjects: 0

Group type: COMPARATOR
Intervention: McDonald cerclage
Number of subjects: 0
Study: 19938213

Group type: EXPERIMENTAL
Intervention: Ear acupuncture stimulation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham-point control
Number of subjects: 14
Study: 17067979

Group type: EXPERIMENTAL
Intervention: Pycnogenol (50 mg capsules, 3 times daily for a total of 150 mg daily) for 8 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (no treatment during the observation period)
Number of subjects: 39
Study: 15526380

Group type: EXPERIMENTAL
Intervention: Selenium (1.156x10(‐7) mol/L) for 6 h in vitro or selenium-yeast (200 microg/d) for 8-12 wk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selenium-yeast (200 microg/d) for 8-12 wk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy blood donors (control group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chronic hepatitis patients (without selenium treatment)
Number of subjects: 0
Study: 10740417

Group type: EXPERIMENTAL
Intervention: Leptin and neuropeptide Y concentrations in pregnant women with EPH gestosis
Number of subjects: 87

Group type: COMPARATOR
Intervention: Leptin and neuropeptide Y concentrations in healthy pregnant women
Number of subjects: 87

Group type: COMPARATOR
Intervention: Leptin and neuropeptide Y concentrations in healthy non-pregnant women
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Correlation of plasma NPY concentration in pregnant women with EPH gestosis
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Correlation of leptinaemia in pregnant women
Number of subjects: 87
Study: 7862419

Group type: EXPERIMENTAL
Intervention: 0.05% levocabastine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 4% sodium cromolyn
Number of subjects: 50
Study: 1778192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 20
Study: 7011467

Group type: EXPERIMENTAL
Intervention: 75 mg of dipyridamole in combination with 30 mg (0.5 mg/kg) of acetylsalicylic acid (ASA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 75 mg of dipyridamole in combination with 50 mg (0.8 mg/kg) of acetylsalicylic acid (ASA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 75 mg of dipyridamole in combination with 160 mg (2.6 mg/kg) of acetylsalicylic acid (ASA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 75 mg of dipyridamole in combination with 330 mg (5.7 mg/kg) of acetylsalicylic acid (ASA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dipyridamole alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dipyridamole-ASA combinations with ASA doses of 0.5 to 0.8 mg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dipyridamole-ASA combinations with ASA doses between 2.6 to 5.7 mg/kg
Number of subjects: 36
Study: 31029154

Group type: EXPERIMENTAL
Intervention: TLP0-001 in combination with S-1
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo in combination with S-1
Number of subjects: 185
Study: 29795561

Group type: EXPERIMENTAL
Intervention: rhTM treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Other treatments (not rhTM)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Decrease in HMGB1
Number of subjects: 36
Study: 26698157

Group type: EXPERIMENTAL
Intervention: Cryoballoon application time of 240 seconds (group 1)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Cryoballoon application time of 180 seconds (group 2)
Number of subjects: 114
Study: 25239028

Group type: EXPERIMENTAL
Intervention: Cycling exercise in hypoxic conditions (simulating 3000 m)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cycling exercise in ambient conditions (975 m)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both hypoxic and ambient cycling exercise
Number of subjects: 11
Study: 23114134

Group type: EXPERIMENTAL
Intervention: Bisphosphonates combined with chemotherapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 53
Study: 19757018

Group type: EXPERIMENTAL
Intervention: Diaphragm and Replens lubricant gel
Number of subjects: 2452
Study: 17721099

Group type: EXPERIMENTAL
Intervention: HAART (Highly Active Antiretroviral Therapy)
Number of subjects: 1160
Study: 15612942

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (PerioGard)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.5% hydrogen peroxide (Peroxyl)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combined chlorhexidine+hydrogen peroxide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 16
Study: 12170139

Group type: EXPERIMENTAL
Intervention: Mastoid cortex plasty with scutum plasty and insertion of a Silastic sheet
Number of subjects: 35

Group type: COMPARATOR
Intervention: Scutum plasty with insertion of a Silastic sheet without mastoid cortex plasty
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups (with and without mastoid cortex plasty)
Number of subjects: 35
Study: 9989957

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study: 7586249

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 0
Study: 31197287

Group type: EXPERIMENTAL
Intervention: Volleyball training for athletes with intellectual disabilities
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy players
Number of subjects: 30
Study: 29231318

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy Control
Number of subjects: 30